Legend Biotech(US:LEGN) Globenewswire·2026-01-12 13:00Core Insights - Legend Biotech Corporation is positioned for transformative growth in 2026, aiming for profitability through the global adoption of its CAR-T therapy, CARVYKTI, which has treated over 10,000 patients [2][5][6] Group 1: Commercial Progress - CARVYKTI has solidified its leadership in multiple myeloma CAR-T cell therapy, achieving a milestone of over 10,000 patients treated [2][6] - The company expanded CARVYKTI's global footprint to over 279 sites across 14 markets in 2025, with plans for further globalization in 2026 [6] - The Raritan facility has been expanded, now being the largest cell therapy manufacturing facility in the U.S., capable of supporting treatment for up to 10,000 patients annually [5][6] Group 2: Clinical Advancements - Promising first-in-human results were presented for the allogeneic CAR-T candidate LUCAR-G39D, showing encouraging safety and efficacy in B-cell non-Hodgkin lymphoma [4] - New clinical data from the CARTITUDE-1 and CARTITUDE-4 trials demonstrated significant benefits of CARVYKTI, including a median progression-free survival (PFS) of 50.4 months for triple-class-exposed patients [6] - The company completed enrollment for the Phase 3 CARTITUDE-6 trial in newly diagnosed multiple myeloma patients who are transplant eligible [6] Group 3: Financial Outlook - The company anticipates achieving profitability in 2026, driven by continued revenue growth from CARVYKTI and operating margin expansion [5][11] - As of September 30, 2025, the company reported approximately $1.0 billion in cash and cash equivalents, providing a financial runway beyond 2026 [11] Group 4: Strategic Priorities - The strategic priorities for 2026 include maximizing CARVYKTI's market leadership and advancing cell therapy innovation [3][5] - The company is committed to leveraging its CAR-T development platform to explore new in vivo and allogeneic opportunities [2][3]